Esomeprazole

⇄

cytochrome P450 family 2 subfamily C member 19 ; Homo sapiens







42 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34791831 Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. 2022 Jan 3
2 35146797 Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. 2022 Jul 1
3 33503046 Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17. 2021 1
4 33953602 Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole. 2021 3
5 34414773 The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis. 2021 Aug 1
6 31657713 Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
. 2020 Jan 3
7 32227647 Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. 2020 Oct 7
8 32558923 Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. 2020 Dec 5
9 30520273 Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. 2019 Mar 1
10 30845361 Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. 2019 Jul 2
11 28875498 Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. 2018 May 2
12 26815196 Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. 2016 Jan 27 4
13 26991399 Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. 2016 May 1
14 27433344 Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines. 2016 Jun 1
15 27991432 The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-13C breath test in GERD patients: clinical relevance for personalized medicine. 2016 Dec 17 2
16 24887634 Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. 2015 Feb 1
17 26159874 CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. 2015 Sep 3
18 24500275 Urinary diazepam metabolite distribution in a chronic pain population. 2014 Apr 1
19 24550106 Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. 2014 Apr 1
20 24590877 Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions. 2014 Aug 2
21 24918808 Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. 2014 May 2
22 25120580 Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. 2014 1
23 22313038 Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. 2012 Jul 1
24 22648560 Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. 2012 Sep 3
25 22649281 Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. 2012 3
26 21455342 Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. 2011 Mar 16 1
27 21771377 [Interaction between clopidogrel and proton pump inhibitors]. 2011 1
28 21795468 The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. 2011 Nov 3
29 21073556 Antiplatelet drug interactions. 2010 Dec 1
30 18751689 Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. 2009 Jan 2
31 18702650 Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. 2008 Sep 1
32 15691303 Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. 2005 Feb 1 1
33 16338278 Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. 2005 Dec 3
34 15166754 Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote. 2004 May 1
35 15245569 CYP2C19 polymorphism and proton pump inhibitors. 2004 Jul 1
36 12680476 Pharmacogenetics of the proton pump inhibitors: a systematic review. 2003 Apr 1
37 15065530 [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors]. 2003 1
38 12236477 Proton pump inhibitors--differences emerge in hepatic metabolism. 2002 Jul 1
39 12495367 Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. 2002 1
40 11430508 New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. 2001 May 2
41 11475467 Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. 2001 2
42 11510629 Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. 2001 1